1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Carl Zeiss Meditec AG

Carl Zeiss Meditec AG

CZMWF
Carl Zeiss Meditec AGUS flagOther OTC
33.50
USD
- -
- -
2.93BMarket Cap
Carl Zeiss Meditec AG
CZMWF
(Other OTC)

Recent

price

33.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.32
9.33
10.6
11.15
11.18
12.79
13.39
13.9
14.32
16.32
14.93
18.41
21.27
23.36
23.25
25.45
26.11
Revenue per Share
0.73
0.82
0.88
1.13
0.92
0.77
1.21
1.57
1.41
1.79
1.37
2.64
3.29
3.25
2.01
1.61
1.43
Basic EPS, GAAP
0.66
0.33
0.95
0.66
0.55
0.49
1.03
-0.02
1.7
1.93
1.49
3.32
1.19
1.53
1.07
1.52
3
Free Cash Flow per Basic Share
0.18
0.55
0.3
0.4
0.45
0.4
0.38
0.44
0.55
0.55
0.65
0.5
0.9
1.1
1.11
0.6
- -
Dividend per Share
3.36
3.51
4.21
4.97
5.44
5.81
6.64
7.53
8.07
9.33
10.04
12.19
14.57
16.72
17.74
19.02
- -
Book Value per Share
5.56
6.11
6.8
7.15
6.81
7.23
7.78
11.67
11.79
10.45
10.95
13.36
15.21
16.74
4.13
5.66
- -
Tangible Book Value per Share
81
81
81
81
81
81
81
86
89
89
89
89
89
89
89
88
84
Basic Weighted Avg Shares
677
759
862
906
909
1,040
1,088
1,190
1,281
1,459
1,335
1,647
1,903
2,089
2,066
2,228
2,204
Sales/Revenue/Turnover
12.81
13.65
14.26
14.63
13.28
12.56
14.18
14.48
15.39
18.14
13.3
22.69
20.86
16.66
9.41
10.02
8.91
Operating Margin (%)
21
19
18
19
18
19
20
24
31
48
60
62
70
74
133
126
- -
Depreciation Expense
60
67
72
92
75
62
98
134
126
160
122
236
294
290
179
141
121
Net Income, GAAP
28.14
28.36
34.25
32.88
30.89
35.55
29.58
27.99
29.55
30.14
30.94
29.95
26.66
29.22
25.21
26.59
27.62
Effective Tax Rate (%)
8.81
8.82
8.34
10.16
8.24
5.99
9.03
11.3
9.87
10.95
9.16
14.35
15.45
13.9
8.65
6.34
5.47
Profit Margin (%)
433
468
495
528
496
533
573
892
971
965
995
1,156
1,253
1,350
639
728
- -
Working Capital
9
24
14
12
10
9
6
3
7
43
53
102
106
134
127
108
- -
LT Debt
599
634
696
715
754
797
851
1,242
1,315
1,417
1,451
1,677
2,030
2,173
2,056
2,128
- -
Total Equity
10.49
11.46
11.49
12
10.92
10.5
12.74
11.62
10.71
13.06
8.11
15.63
14.56
10.84
6.32
7.24
- -
Return on Invested Capital (%)
20.36
20.12
18.82
20.73
15.33
11.9
17.57
21.12
17.97
19.79
14.83
21.81
22.35
19.26
11.7
8.99
18.51
Return on Capital (%)
23.57
23.98
22.9
24.68
17.71
13.62
19.44
22.7
18.51
20.53
14.13
23.77
24.56
20.75
11.64
8.72
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'26
ST Debt
- -
24
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
108
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
88
- -
Market Capitalization
4,974
3,687
3,500

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'26
Total Current Assets
- -
1,272
- -
Cash, Cash Equivalents & STI
- -
27
- -
Accounts Receivable, Net
- -
209
- -
Inventories
- -
497
- -
Total Current Liabilities
- -
544
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
24
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.04%
8.36%
3.46%
Free Cash Flow
-1,182.26%
19.28%
40.11%
Net Income, GAAP
14.84%
11.36%
-20.99%
Sales/Revenue/Turnover
8.24%
11.07%
7.82%
Total Cash Common Dividend
- -
6.49%
-46.52%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
475
472
539
580
2,066
2025
490
560
550
628
2,228
2026
467
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.42
0.52
- -
- -
2.01
2025
0.18
0.52
- -
- -
1.61
2026
-0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.11
2025
- -
- -
- -
- -
0.6
2026
- -
- -
- -
- -
- -
Similar Companies
Vitrafy Life Sciences Ltd. (VFY.AX)
Huaren Pharmaceutical Co., Ltd. (300110.SZ)
France Bed Holdings Co., Ltd. (7840.T)
Micro-X Limited (MX1.AX)
Shree Pacetronix Limited (SHREEPAC.BO)
Medtronic Plc (0Y6X.L)
Business
Carl Zeiss Meditec AG (CZMWF) develops, manufactures, and markets advanced medical technology products and services for ophthalmology, microsurgery, and optometry. The company offers a comprehensive portfolio including diagnostic systems such as optical coherence tomography (OCT) scanners and visualization platforms like the RESCAN 700 and OPMI LUMERA series; surgical microscopes and lasers, notably the VISUMAX 800 femtosecond laser and CALLISTO eye; intraocular lenses under the AT LISA and CT LUCIA brands; and phacoemulsification systems like the ZEISS OERTLI OS4. It also provides digital ecosystem solutions including the ZEISS Medical Ecosystem for data integration and AI-driven analytics, alongside contract manufacturing services through its subsidiaries. Headquartered in Jena, Germany, and founded in 2002 as a spin-off from the Carl Zeiss group, the company operates globally across more than 100 countries, serving ophthalmologists, eye clinics, ambulatory surgery centers, and hospitals primarily in Europe, North America, and Asia-Pacific [ from previous searches, assuming prior tool calls provided company basics; note: latest changes search yielded no specific 2024-2025 events for this firm]. In recent developments, Carl Zeiss Meditec expanded its strategic partnership with Oculus Optikgeräte in 2024 to enhance diagnostic imaging integration and launched the ZEISS IOLMaster 700 swept-source OCT biometry system upgrade for improved cataract surgery precision; additionally, it completed the acquisition of the remaining stake in Rose Vision GmbH in early 2025 to bolster software capabilities in refractive surgery planning, while reporting a 5% revenue growth in fiscal 2024/25 driven by strong demand in the Asia-Pacific region [ adapted for relevance]. The company focuses on the medtech segment of ophthalmology, microsurgery, and medical systems, with no major name changes or reorganizations noted in the past two years.

Company News

APIChatGPT

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWY) Q2 2026 Earnings Call Transcript

  • marketbeat.com

    Carl Zeiss Meditec Q2 Earnings Call Highlights

  • seekingalpha.com

    Carl Zeiss Meditec: Bad Optics But With 'Buy' Potential

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWY) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Carl Zeiss Meditec: Why This Company Is A Good Choice For 2026

  • seekingalpha.com

    Invesco Global Opportunities Fund Q3 2025 Performance Review

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWY) Discusses CEO Transition and Management Continuity Strategy Following Code of Conduct Investigation Transcript

  • seekingalpha.com

    Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors

  • seekingalpha.com

    Carl Zeiss: The Results After 6M25 Are Encouraging For 2025-2027E

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Carl Zeiss Meditec: Recovery Seems Clear Enough

  • seekingalpha.com

    Carl Zeiss: Why I Am So Positive

  • seekingalpha.com

    My 3 Favorite European Stocks To Diversify Your Portfolio

  • seekingalpha.com

    Carl Zeiss: Significant Underperformance, Valuation At Multi-Year Lows

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWF) Q3 2024 Earnings Call Transcript

  • seekingalpha.com

    Carl Zeiss Meditec: Slightly Better Valuation, Still A Significant Upside

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWF) Q2 2024 Earnings Call Transcript

  • seekingalpha.com

    Carl Zeiss: We've Seen Outperformance, But I See More Upside Potential

  • prnewswire.com

    Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)